SMIM1

Summary

SMIM1 (small integral membrane protein 1 (Vel blood group), HGNC:44204) is a protein-coding gene on chromosome 1p36.32, encoding Small integral membrane protein 1 (B2RUZ4). Regulator of red blood cell formation.

This gene encodes a small, conserved protein that participates in red blood cell formation. The encoded protein is localized to the cell membrane and is the antigen for the Vel blood group. Alternative splicing results in different transcript variants that encode the same protein.

Source: NCBI Gene 388588 — RefSeq curated summary.

At a glance

• GWAS associations: 27
• Clinical variants (ClinVar): 11 total
• MANE Select transcript: NM_001288583

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:44204
Approved symbol	SMIM1
Name	small integral membrane protein 1 (Vel blood group)
Location	1p36.32
Locus type	gene with protein product
Status	Approved
Aliases	Vel
Ensembl gene	ENSG00000235169
Ensembl biotype	protein_coding
OMIM	615242
Entrez	388588

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 11 protein_coding

ENST00000444870, ENST00000452264, ENST00000561886, ENST00000642557, ENST00000863967, ENST00000863968, ENST00000863969, ENST00000863970, ENST00000863971, ENST00000966426, ENST00000966427

RefSeq mRNA: 4 — MANE Select: NM_001288583 NM_001163724, NM_001288583, NM_001379690, NM_001379691

CCDS: CCDS57966

Canonical transcript exons

ENST00000642557 — 4 exons

Exon	Start	End
ENSE00001646997	3773063	3773181
ENSE00001760122	3775299	3775483
ENSE00003823375	3775795	3775956
ENSE00003825847	3772749	3772788

Expression profiles

Bgee: expression breadth ubiquitous, 168 present calls, max score 92.84.

FANTOM5 (CAGE): breadth broad, TPM avg 3.0967 / max 154.6030, expressed in 883 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
327	1.3378	325
325	1.2119	553
326	0.5469	297

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	92.84	gold quality
left testis	UBERON:0004533	92.28	gold quality
right atrium auricular region	UBERON:0006631	91.88	gold quality
cardiac atrium	UBERON:0002081	90.73	gold quality
testis	UBERON:0000473	90.02	gold quality
parotid gland	UBERON:0001831	88.58	gold quality
apex of heart	UBERON:0002098	87.83	gold quality
adenohypophysis	UBERON:0002196	85.33	gold quality
blood	UBERON:0000178	84.90	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.21	gold quality
right lobe of liver	UBERON:0001114	84.15	gold quality
trabecular bone tissue	UBERON:0002483	84.15	gold quality
pituitary gland	UBERON:0000007	83.57	gold quality
bone marrow	UBERON:0002371	82.99	gold quality
bone marrow cell	CL:0002092	82.38	gold quality
heart	UBERON:0000948	81.62	gold quality
pancreatic ductal cell	CL:0002079	81.50	silver quality
heart left ventricle	UBERON:0002084	81.40	gold quality
kidney epithelium	UBERON:0004819	81.31	gold quality
cardiac ventricle	UBERON:0002082	81.15	gold quality
adult mammalian kidney	UBERON:0000082	81.06	gold quality
saliva-secreting gland	UBERON:0001044	80.80	gold quality
left lobe of thyroid gland	UBERON:0001120	79.99	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	79.66	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	79.59	gold quality
minor salivary gland	UBERON:0001830	79.55	gold quality
upper arm skin	UBERON:0004263	79.38	gold quality
body of pancreas	UBERON:0001150	78.95	gold quality
left ovary	UBERON:0002119	78.79	gold quality
right lobe of thyroid gland	UBERON:0001119	78.76	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-MTAB-9388	yes	330.54
E-MTAB-8205	yes	201.64
E-HCAD-4	yes	160.47
E-HCAD-6	yes	60.21
E-CURD-112	yes	52.86
E-MTAB-10042	yes	45.35
E-HCAD-10	yes	30.29
E-GEOD-134144	yes	29.46
E-MTAB-3929	yes	26.23
E-MTAB-9221	yes	12.21
E-ANND-3	yes	11.30
E-HCAD-9	yes	7.85
E-MTAB-9067	no	3.23
E-MTAB-9801	no	2.74
E-MTAB-9467	no	1.11

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 14)

• A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM1. (PMID:23505126)
• Loss of SMIM1 is associated with reduction in red blood cell formation. (PMID:23563606)
• Loss of SMIM1 is associated with reduction in red blood cell formation. (PMID:23563608)
• Weak Vel expression levels are caused by multiple genetic factors in SMIM1 and probably also by other genetic or environmental factors. (PMID:25647324)
• SMIM1 carries the Vel antigen as a type II membrane protein with a predicted C-terminal extracellular domain of only 3-12 amino acids (PMID:26452714)
• Alleles that initially entered the population have been maintained within the population. The c.64_80del null allele of SMIM1 is one such allele, thus having implications for transfusion medicine and child or maternal health. (PMID:26666208)
• Among the 448 samples analysed, 10 (2.23%) harboured the 17 bp deletion of the gene SMIM1, and all were heterozygote for the SMIM1*64_80 del allele. (PMID:27328373)
• rs1175550G and to a lesser extent rs143702418C independently increase SMIM1 and Vel antigen expression. (PMID:28084402)
• the present study demonstrated that although the SMIM1*64_80del allele is responsible for some variation of Vel phenotype in this donor population, Vel expression is also controlled by molecular changes in SMIM1 intron 2. (PMID:29517970)
• Identification of a novel single-nucleotide mutation in SMIM1 gene that results in low Vel antigen expression. (PMID:31218697)
• Dimerization of small integral membrane protein 1 promotes cell surface presentation of the Vel blood group epitope. (PMID:31879955)
• SMIM1, carrier of the Vel blood group, is a tail-anchored transmembrane protein and readily forms homodimers in a cell-free system. (PMID:32301496)
• SMIM1 missense mutations exert their effect on wild type Vel expression late in erythroid differentiation. (PMID:33128268)
• SMIM1 absence is associated with reduced energy expenditure and excess weight. (PMID:38906141)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Smim1	ENSMUSG00000078350
rattus_norvegicus	Smim1	ENSRNOG00000080057

Protein

Protein identifiers

Small integral membrane protein 1 — B2RUZ4 (reviewed: B2RUZ4)

Alternative names: Vel blood group antigen

All UniProt accessions (4): B2RUZ4, A0A2R8Y7R4, H3BS66, M4WDD3

UniProt curated annotations — full annotation on UniProt →

Function. Regulator of red blood cell formation.

Subunit / interactions. Homooligomer; disulfide-linked.

Subcellular location. Cell membrane.

Tissue specificity. Highly expressed in the bone marrow and expressed at lower levels in non-hematopoietic tissues. Highly expressed in erythroleukemia cell lines. Up-regulated in CD34+ hematopoietic progenitors cultured toward red blood cells.

Domain organisation. The extracellular domain carries the Vel antigen.

Polymorphism. SMIM1 is responsible for the Vel blood group system (VEL) [MIM:615264]. The Vel antigen is present on red blood cells from all people except rare Vel-negative individuals who can form antibodies to Vel in response to transfusion or pregnancy. These antibodies may cause severe hemolytic reactions in blood recipients. In most cases, Vel-negative individuals are homozygous for a 17-nucleotide frameshift deletion in exon 3. In some cases, Vel-negative are heterozygous for the 17-nucleotide frameshift deletion and a missense variant at position 51.

Similarity. Belongs to the SMIM1 family.

RefSeq proteins (4): NP_001157196, NP_001275512, NP_001366619, NP_001366620 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR031744	SMIM1	Family

Pfam: PF15875

UniProt features (21 total): mutagenesis site 7, modified residue 5, topological domain 2, sequence variant 2, region of interest 2, chain 1, transmembrane region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-B2RUZ4-F1	70.79	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 22, 27, 1, 6, 17

Mutagenesis-validated functional residues (7):

Position	Phenotype
6	no effect on cell membrane localization; when associated with a-17; a-22 and a-27. no effect on cell surface expression
17	no effect on cell membrane localization; when associated with a-6; a-22 and a-27. no effect on cell surface expression o
22	no effect on cell membrane localization; when associated with a-6; a-17 and a-27. no effect on cell surface expression o
27	no effect on cell membrane localization; when associated with a-6; a-17 and a-22. no effect on cell surface expression o
35	no effect on cell surface expression of the vel antigen; when associated with s-43.
43	no effect on cell surface expression of the vel antigen; when associated with s-35.
76–78	loss of cell-surface expression of the vel antigen.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 52 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_MYELOID_CELL_DEVELOPMENT, GOBP_ERYTHROCYTE_HOMEOSTASIS, GOCC_CELL_SURFACE, CHANDRAN_METASTASIS_DN, GUO_HEX_TARGETS_DN, GOBP_MULTICELLULAR_ORGANISMAL_LEVEL_HOMEOSTASIS, GOBP_ERYTHROCYTE_DEVELOPMENT, GOBP_HOMEOSTATIC_PROCESS, GOMF_PROTEIN_DIMERIZATION_ACTIVITY, GOMF_PROTEIN_HOMODIMERIZATION_ACTIVITY, GOBP_HOMEOSTASIS_OF_NUMBER_OF_CELLS, chr1p36, CHYLA_CBFA2T3_TARGETS_DN

GO Biological Process (0):

GO Molecular Function (2): protein homodimerization activity (GO:0042803), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
identical protein binding	1
protein dimerization activity	1
binding	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

212 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SMIM1	HDX	Q7Z353	572
SMIM1	SMIM3	Q9BZL3	530
SMIM1	NME7	Q9Y5B8	463
SMIM1	SMIM2	Q9BVW6	446
SMIM1	PRRT4	C9JH25	430
SMIM1	DOK3	Q7L591	388
SMIM1	ATP6AP1L	Q52LC2	388
SMIM1	EFCAB8	A8MWE9	377
SMIM1	MTG1	Q9BT17	366
SMIM1	NPL	Q9BXD5	348
SMIM1	VPS37A	Q8NEZ2	343
SMIM1	TRO	Q12816	325
SMIM1	GATA1	P15976	323
SMIM1	RHCE	P18577	318
SMIM1	KEL	P23276	314

IntAct

172 interactions, top by confidence:

A	B	Type	Score
SMIM1	TMX2	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	LHFPL5	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	HACD2	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	CYB561	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	COMT	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	STING1	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	NDUFAF2	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	HSD17B13	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	SLC26A11	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	ANKS6	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	STX1A	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	MFF	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	CD74	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	BCL2L13	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	BIK	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	NAALAD2	psi-mi:“MI:0915”(physical association)	0.560
SDC3	SMIM1	psi-mi:“MI:0915”(physical association)	0.560
	SMIM1	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	CREB3L1	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	TMPRSS2	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	AQP6	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (62): SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid), SMIM1 (Two-hybrid)

ESM2 similar proteins: A4IG66, B2RUZ4, B3DHH5, F1NVK6, F1Q930, O70367, O76024, O77770, O95772, P02683, P0C8K7, P42857, P56695, P84889, Q0P4Z1, Q15053, Q1JPG0, Q28DG6, Q2TBG9, Q4QQM5, Q4R5Q3, Q56JY4, Q5BLE2, Q5M836, Q5RF46, Q5XJS0, Q5ZKK0, Q62092, Q6GR21, Q6IQA2, Q6NRB7, Q6P606, Q7L4E1, Q7Z3D4, Q8BG50, Q8BK03, Q8BXV2, Q8IUW5, Q8K2J7, Q8NAN2

Diamond homologs: B2RUZ4, B3DHH5, P0C8K7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

11 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	8
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

642 predictions. Top by Δscore:

Variant	Effect	Δscore
1:3773169:C:T	donor_gain	0.9900
1:3773180:GG:G	donor_gain	0.9900
1:3773181:GG:G	donor_gain	0.9900
1:3773181:GGTAA:G	donor_loss	0.9900
1:3773182:GTAA:G	donor_loss	0.9900
1:3773183:T:A	donor_loss	0.9900
1:3773653:G:GT	donor_gain	0.9900
1:3773677:G:GT	donor_gain	0.9900
1:3773725:C:G	donor_gain	0.9900
1:3775297:A:AG	acceptor_gain	0.9900
1:3775298:G:GG	acceptor_gain	0.9900
1:3775387:A:T	donor_gain	0.9900
1:3775405:G:GG	donor_gain	0.9900
1:3773182:G:GG	donor_gain	0.9800
1:3773184:AAGT:A	donor_loss	0.9800
1:3773739:A:T	donor_gain	0.9800
1:3775298:GT:G	acceptor_gain	0.9800
1:3775298:GTGA:G	acceptor_gain	0.9800
1:3773724:GCTGG:G	donor_gain	0.9700
1:3773646:G:GT	donor_gain	0.9600
1:3775298:GTGAA:G	acceptor_gain	0.9600
1:3772866:GC:G	donor_gain	0.9500
1:3773753:G:GA	donor_gain	0.9500
1:3773750:G:GA	donor_gain	0.9400
1:3775793:AG:A	acceptor_gain	0.9400
1:3775794:GG:G	acceptor_gain	0.9400
1:3772839:C:T	donor_gain	0.9200
1:3773179:CGG:C	donor_gain	0.9200
1:3773180:GGG:G	donor_gain	0.9200
1:3773637:TC:T	donor_gain	0.9200

AlphaMissense

471 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:3775883:G:C	G67R	0.908
1:3775884:G:A	G67D	0.896
1:3775865:T:A	W61R	0.877
1:3775865:T:C	W61R	0.877
1:3775412:G:C	W13C	0.860
1:3775412:G:T	W13C	0.860
1:3775896:G:A	G71D	0.850
1:3775874:T:C	F64L	0.822
1:3775876:C:A	F64L	0.822
1:3775876:C:G	F64L	0.822
1:3775895:G:C	G71R	0.816
1:3775893:C:A	T70K	0.765
1:3775886:T:G	Y68D	0.747
1:3775840:G:C	K52N	0.742
1:3775840:G:T	K52N	0.742
1:3775851:G:A	G56D	0.723
1:3775898:T:G	Y72D	0.721
1:3775862:T:C	F60L	0.714
1:3775864:C:A	F60L	0.714
1:3775864:C:G	F60L	0.714
1:3775410:T:A	W13R	0.706
1:3775410:T:C	W13R	0.706
1:3775895:G:T	G71C	0.693
1:3775875:T:C	F64S	0.673
1:3775893:C:G	T70R	0.669
1:3775857:C:A	A58D	0.666
1:3775883:G:T	G67C	0.663
1:3775884:G:T	G67V	0.663
1:3775886:T:C	Y68H	0.658
1:3775896:G:T	G71V	0.642

dbSNP variants (sampled 300 via entrez): RS1000308514 (1:3772261 C>T), RS1001074497 (1:3771965 C>A), RS1001232288 (1:3773192 G>A), RS1001263621 (1:3773512 C>G,T), RS1002088396 (1:3770981 A>G), RS1002229863 (1:3774464 C>T), RS1002280807 (1:3774685 C>G,T), RS1002280963 (1:3776008 C>A,G,T), RS1002886403 (1:3775167 T>C), RS1003825750 (1:3776220 G>A,C), RS1003835618 (1:3776402 G>C), RS1004033438 (1:3771083 G>C), RS1004171101 (1:3774419 G>A), RS1004489578 (1:3771297 G>A,C), RS1004827898 (1:3775258 A>C,G)

Disease associations

OMIM: gene MIM:615242 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

27 associations (top):

Study	Trait	p-value
GCST004601_1	Red blood cell count	9.000000e-13
GCST004605_1	Mean corpuscular hemoglobin concentration	1.000000e-43
GCST004611_101	High light scatter reticulocyte count	1.000000e-49
GCST004612_191	High light scatter reticulocyte percentage of red cells	2.000000e-43
GCST004619_15	Reticulocyte fraction of red cells	3.000000e-34
GCST004621_1	Red cell distribution width	1.000000e-17
GCST004622_99	Reticulocyte count	2.000000e-42
GCST004628_1	Immature fraction of reticulocytes	3.000000e-27
GCST006804_195	Red cell distribution width	5.000000e-12
GCST010083_47	Hemoglobin levels	1.000000e-28
GCST90002383_142	Hematocrit	9.000000e-10
GCST90002384_523	Hemoglobin	2.000000e-33
GCST90002385_597	High light scatter reticulocyte count	8.000000e-85
GCST90002385_598	High light scatter reticulocyte count	2.000000e-17
GCST90002386_302	High light scatter reticulocyte percentage of red cells	5.000000e-72
GCST90002386_303	High light scatter reticulocyte percentage of red cells	5.000000e-16
GCST90002387_188	Immature fraction of reticulocytes	1.000000e-38
GCST90002391_52	Mean corpuscular hemoglobin concentration	8.000000e-93
GCST90002392_147	Mean corpuscular volume	7.000000e-20
GCST90002397_168	Mean spheric corpuscular volume	6.000000e-80
GCST90002403_29	Red blood cell count	3.000000e-24
GCST90002404_424	Red cell distribution width	4.000000e-46
GCST90002404_450	Red cell distribution width	5.000000e-42
GCST90002405_587	Reticulocyte count	9.000000e-79
GCST90002405_588	Reticulocyte count	1.000000e-16
GCST90002406_126	Reticulocyte fraction of red cells	1.000000e-64
GCST90002406_127	Reticulocyte fraction of red cells	5.000000e-15

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004305	erythrocyte count
EFO:0004528	mean corpuscular hemoglobin concentration
EFO:0007986	reticulocyte count
EFO:0009188	Red cell distribution width
EFO:0004509	hemoglobin measurement
EFO:0004348	hematocrit

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	decreases expression, increases abundance, increases expression	2
Particulate Matter	decreases expression, decreases reaction, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
afuresertib	increases expression	1
FR900359	affects phosphorylation	1
propionaldehyde	increases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Sunitinib	decreases expression	1
Vehicle Emissions	decreases expression, decreases reaction	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Caffeine	increases phosphorylation	1
Copper	affects abundance	1
Smoke	decreases expression, increases abundance	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases methylation	1
Okadaic Acid	decreases expression	1
S-Nitrosoglutathione	increases expression	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery